Efficacy and safety of bimekizumab in the treatment of genital psoriasis: A case series.

The article discusses a case series evaluating the effectiveness of bimekizumab in treating genital psoriasis (GenPs) over 52 weeks. Twelve patients with moderate-to-severe GenPs were treated with bimekizumab, showing significant improvement in their condition. The study highlights bimekizumab's sustained positive trend in managing GenPs, with patients achieving clear/almost clear status and improved quality of life. While some patients experienced minor side effects, the overall response to treatment was consistent across different sexes and prior treatment experiences. [Extracted from the article]